Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio, Inc. (NASDAQ: ACET), a biotechnology company specializing in allogeneic gamma delta T cell therapies for cancer, announced on March 31, 2023, that it granted new hires stock options to purchase 237,400 shares at an exercise price of $5.76 each. This award was given to ten individuals hired in March 2023 and vests over four years, contingent upon continued employment. The awards were issued in accordance with the 2022 Inducement Plan, which was approved by the board of directors. This strategy aligns with Nasdaq rules aimed at incentivizing employee recruitment.

Adicet Bio, Inc. (Nasdaq: ACET) has reported interim safety and efficacy data for ADI-001, showing a 75% overall response rate and a 69% complete response rate in a Phase 1 study for relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The company is set to provide further data in Q2 2023 and plans to discuss potential pivotal study designs with the FDA. Financially, while R&D expenses for Q4 2022 rose to $25 million, leading to a net loss of $29.9 million, cash reserves stood at $257.7 million, sufficient to fund operations into 2025. New preclinical data and in-house manufacturing capabilities were also highlighted.

Adicet Bio, a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer, announced participation in the 2023 Jefferies Biotech on the Bay Summit from March 16-17, 2023. Representing the company will be Chen Schor, President and CEO, and Nick Harvey, CFO. Adicet Bio aims to enhance tumor targeting and anti-tumor immune response with its engineered gamma delta T cells. The team will hold one-on-one meetings at the conference, providing opportunities for deeper engagement with investors and partners. For more information, visit Adicet's website.

Adicet Bio, Inc. (NASDAQ: ACET) announced the granting of inducement awards on February 28, 2023, to four employees hired in February 2023. These awards consist of non-qualified stock options totaling 105,400 shares at an exercise price of $7.88 per share, equal to the stock’s closing price on the grant date. Vesting is structured with 25% after one year and the remaining shares vesting in 36 equal monthly installments, dependent on continued employment. The awards were made under the company’s 2022 Inducement Plan, authorized by the board's independent compensation committee, in compliance with Nasdaq rules.

Adicet Bio, Inc. (Nasdaq: ACET) is set to have its President and CEO, Chen Schor, participate in a fireside chat at the 2023 Guggenheim Oncology Conference on February 9, 2023, at 2:10 p.m. ET. This conference focuses on the development of allogeneic gamma delta T cell therapies for cancer, which are engineered to enhance tumor targeting and boost immune responses. Investors can access the live audio webcast on Adicet's website, with an archived replay available for 30 days post-event. For further details on Adicet's innovative therapies, visit Adicet Bio's website.

Adicet Bio, Inc. (NASDAQ: ACET) announced on January 31, 2023, that it granted inducement awards to six new employees, comprising non-qualified stock options for 72,800 shares at an exercise price of $9.15. These options will vest over four years, with one-fourth vesting on the one-year anniversary of each employee's start date and the remainder vesting in thirty-six equal monthly installments. This award was granted pursuant to the 2022 Inducement Plan, amended in January 2023, endorsed by the independent compensation committee to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio, Inc. (ACET) reported positive Phase 1 trial results for its investigational therapy, ADI-001, targeting relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). As of December 5, 2022, ADI-001 exhibited a 75% overall response rate (ORR) and a 69% complete response (CR) rate across all doses. Notably, in five patients previously treated with CAR T therapy, the ORR and CR were both 100%. The company aims to initiate pivotal studies in 2023, potentially leading to regulatory applications. No significant safety issues were reported, with treatment deemed well-tolerated.

Adicet Bio, Inc. (NASDAQ: ACET) will host a webcast on December 11, 2022, at 9:00 a.m. EST, to discuss the latest data from its Phase 1 study of ADI-001, targeting relapsed or refractory B-cell NHL. The presentation will feature Dr. Sattva Neelapu from MD Anderson Cancer Center, along with the Adicet management team. Participants can register on Adicet's website. An archived replay will be accessible for 30 days post-event. The company is focused on allogeneic gamma delta T cell therapies for cancer treatment.

Adicet Bio, Inc. (NASDAQ: ACET) announced on November 30, 2022, the grant of inducement awards to three new employees, totaling 38,400 stock options with an exercise price of $18.18 per share. Additionally, Dr. Nancy Boman, the company's newly appointed Senior VP and Chief Regulatory Officer, received an award for 136,000 stock options at the same exercise price. The options will vest over four years, contingent on continued employment. These grants were made outside the stockholder-approved equity plans, aligning with Nasdaq rules.